Press releases
These press releases are intended for journalists and analysts/investors.
-
GSK statement on affordability of vaccines in developing countries
More children from the world’s poorest countries are being vaccinated against more diseases than ever before
-
Adelaide Hills Bushfires: Donation of asthma medication
GSK has responded to the South Australian bushfire emergency by providing eight pharmacies in the Adelaide Hills fire affected areas
-
Incruse® Ellipta® (umeclidinium) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease
GlaxoSmithKline (GSK) has welcomed the listing of Incruse Ellipta (umeclidinium) on the Australian Pharmaceutical Benefits Scheme (PBS)
-
Anoro® Ellipta® (umeclidinium/vilanterol) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease
GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) have welcomed news that Anoro Ellipta (umeclidinium/vilanterol) will be reimbursed
-
Breo® Ellipta® (fluticasone furoate/vilanterol) to be PBS listed as reimbursed treatment for asthma and COPD
Affordable treatment options for Australian patients with asthma and chronic obstructive pulmonary disease (COPD) are set to expand
-
GSK announces multi-million dollar investment in next generation manufacturing
GSK Australia has announced today it will be investing AUD$31 million in next generation manufacturing technology
-
Indigenous and refugee programs win immunisation boost
Winners are from across Australia and include medical groups in Mildura, Townsville, Geraldton and Brisbane. They each receive $20,000
-
GSK transitions to online versions of Consumer Medicine Information (CMI) leaflets for prescription only medicines
To ensure we provide the most up-to-date consumer medicine information (CMI) to patients, GSK will no longer be providing CMI leaflets
-
Plant drugs and snail venom: Revolutionary drug research wins GSK award
Plants with peptide-based drugs in their seeds and leaves, and pain relief from cone snail venom are two of the innovative applications
-
Pharmacy/Wholesaler level recall of two batches of Zovirax® Ophthalmic Ointment (aciclovir 3%)
Zovirax® Ophthalmic Ointment is used to treat herpes simplex virus infections of the cornea of the eye.
-
Arzerra® (ofatumumab) registered in Australia for first-line use in chronic lymphocytic leukaemia (CLL)
GlaxoSmithKline announced today that the Therapeutic Goods Administration (TGA) has registered Arzerra® (ofatumumab)
-
International collaboration to develop inhaled form of oxytocin to manage bleeding after childbirth
GSK, Monash University, McCall MacBain Foundation, Grand Challenges Canada and Planet Wheeler Foundation join forces to develop oxytocin
-
Night time bathroom visits - a trigger for men to visit the doctor
Men aged over 50 are being encouraged to see their doctor if they visit the bathroom more than once during the night
-
Kimbra launches campaign to urge effective asthma management
Asthma Awareness Week – Popular recording artist and asthma sufferer Kimbra is joining forces with asthma experts and peak respiratory
-
Medicines Research Unit to Close
GSK today announced it will be closing the Medicines Research Unit at the Prince of Wales Hospital in Sydney
-
GSK Open Innovation brings opportunities to Australian & NZ innovators
Australian and New Zealand health innovators encouraged to apply for partnership with GSK to turn their ideas into reality
-
GSK Response to Publication of Paracetamol in Low Back Pain Study (PACE)
Panadol is approved by the TGA for the effective relief of backache
-
New medicine for lupus now available in Australia
GSK is pleased to announce that BENLYSTA® (belimumab) is now available in Australia for use as an add-on therapy in adult patients
-
Incruse® Ellipta® (umeclidinium) approved in Australia for Chronic Obstructive Pulmonary Disease
GlaxoSmithKline has announced today that the Therapeutic Goods Administration (TGA) has approved Incruse® Ellipta® (umeclidinium)
-
Anoro® Ellipta® approved in Australia for Chronic Obstructive Pulmonary Disease
GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) have proudly announced that the Therapeutic Goods Administration
